Vertex Pharmaceuticals announces the reimbursement of ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) in Australia, a groundbreaking once-daily treatment for cystic fibrosis patients aged 6 and above with at least one responsive mutation in the CFTR gene.
This announcement marks a significant milestone in Vertex's commitment to innovation, as ALYFTREK is the first once-daily CFTR modulator available in Australia, simplifying treatment for patients. With this reimbursement, approximately 3,200 Australians living with cystic fibrosis can now access this cutting-edge therapy.
Cystic fibrosis is a life-shortening genetic disease affecting around 3,800 individuals in Australia. ALYFTREK, a triple-combination CFTR modulator, targets the root cause of CF by enhancing the function of the faulty CFTR protein. It is the fifth CFTR modulator in Australia but the first once-daily option, offering a more convenient treatment regimen.
Elisha Whitfield, Senior Country Manager of Vertex Pharmaceuticals ANZ, emphasizes the impact of this development, stating that over 95% of Australians with cystic fibrosis now have access to a CFTR modulator. The reimbursement is based on global clinical trials and real-world evidence, ensuring the safety and efficacy of ALYFTREK for patients aged 6 and above.
ALYFTREK's inclusion in the Pharmaceutical Benefits Scheme (PBS) is a crucial step in improving the lives of cystic fibrosis patients. Patients and caregivers are advised to consult their healthcare professionals to determine if ALYFTREK is suitable for their specific needs. The PBS listing includes detailed information on side effects, precautions, and dosing instructions.
Vertex Pharmaceuticals, a global biotechnology leader, continues to innovate in the field of cystic fibrosis treatment, offering transformative medicines for those with serious diseases and conditions. With a focus on scientific advancement, Vertex has approved therapies for cystic fibrosis, sickle cell disease, and transfusion-dependent beta thalassemia, among others. The company's commitment to improving patient outcomes is evident in its diverse clinical pipeline and recognition as one of the top places to work in the industry.
